Igm Biosciences Stock Performance
| IGMS Stock | USD 10.79 0.75 7.47% |
On a scale of 0 to 100, IGM Biosciences holds a performance score of 4. The company retains a Market Volatility (i.e., Beta) of 1.96, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, IGM Biosciences will likely underperform. Please check IGM Biosciences' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether IGM Biosciences' current trending patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in IGM Biosciences are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak primary indicators, IGM Biosciences unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.74) | Five Day Return 6.24 | Year To Date Return 15.67 | Ten Year Return (58.68) | All Time Return (58.68) |
1 | Disposition of 925 shares by Lisa Decker of IGM Biosciences at 11.5388 subject to Rule 16b-3 | 09/13/2024 |
2 | IGM Biosciences, Inc. CEO Fred Schwarzer Sells 3,946 Shares | 09/18/2024 |
3 | While shareholders of IGM Biosciences are in the black over 1 year, those who bought a week ago arent so fortunate | 09/27/2024 |
4 | IGM Biosciences downgraded to Hold, stock falls | 10/01/2024 |
5 | Acquisition by Harler Mary Beth of 185000 shares of IGM Biosciences subject to Rule 16b-3 | 10/02/2024 |
6 | Acquisition by Baker Bros. Advisors Lp of 1994 shares of IGM Biosciences subject to Rule 16b-3 | 10/04/2024 |
7 | Acquisition by Bruce Keyt of 24019 shares of IGM Biosciences subject to Rule 16b-3 | 10/25/2024 |
8 | Disposition of 55000 shares by Misbah Tahir of IGM Biosciences at 40.27 subject to Rule 16b-3 | 11/01/2024 |
9 | IGM Biosciences Is In A Good Position To Deliver On Growth Plans | 11/07/2024 |
10 | IGM Biosciences Insiders Who Sold Avert US165m Market Cap Dip | 11/12/2024 |
11 | Acquisition by Misbah Tahir of 66667 shares of IGM Biosciences subject to Rule 16b-3 | 11/18/2024 |
12 | Brokerages Set IGM Biosciences, Inc. PT at 16.13 | 11/27/2024 |
| Begin Period Cash Flow | 121.9 M | |
| Free Cash Flow | -204.6 M |
IGM |
IGM Biosciences Relative Risk vs. Return Landscape
If you would invest 986.00 in IGM Biosciences on September 3, 2024 and sell it today you would earn a total of 93.00 from holding IGM Biosciences or generate 9.43% return on investment over 90 days. IGM Biosciences is currently generating 0.4112% in daily expected returns and assumes 7.5378% risk (volatility on return distribution) over the 90 days horizon. In different words, 67% of stocks are less volatile than IGM, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
IGM Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IGM Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as IGM Biosciences, and traders can use it to determine the average amount a IGM Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0546
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IGMS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.54 actual daily | 67 67% of assets are less volatile |
Expected Return
| 0.41 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average IGM Biosciences is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IGM Biosciences by adding it to a well-diversified portfolio.
IGM Biosciences Fundamentals Growth
IGM Stock prices reflect investors' perceptions of the future prospects and financial health of IGM Biosciences, and IGM Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IGM Stock performance.
| Return On Equity | -1.32 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (124.78) % | ||||
| Current Valuation | 424.09 M | ||||
| Shares Outstanding | 34.08 M | ||||
| Price To Earning | (7.72) X | ||||
| Price To Book | 7.56 X | ||||
| Price To Sales | 212.55 X | ||||
| Revenue | 2.13 M | ||||
| Gross Profit | 1.07 M | ||||
| EBITDA | (253.36 M) | ||||
| Net Income | (246.42 M) | ||||
| Cash And Equivalents | 469.14 M | ||||
| Cash Per Share | 10.95 X | ||||
| Total Debt | 40.51 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 10.79 X | ||||
| Book Value Per Share | 1.33 X | ||||
| Cash Flow From Operations | (192.23 M) | ||||
| Earnings Per Share | (3.61) X | ||||
| Market Capitalization | 620.21 M | ||||
| Total Asset | 423.41 M | ||||
| Retained Earnings | (821.24 M) | ||||
| Working Capital | 305.12 M | ||||
| Current Asset | 1.23 M | ||||
| Current Liabilities | 3.37 M | ||||
About IGM Biosciences Performance
Assessing IGM Biosciences' fundamental ratios provides investors with valuable insights into IGM Biosciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the IGM Biosciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.7 K | -1.8 K | |
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.69) | (0.73) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.21) | (1.15) |
Things to note about IGM Biosciences performance evaluation
Checking the ongoing alerts about IGM Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for IGM Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| IGM Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.13 M. Net Loss for the year was (246.42 M) with profit before overhead, payroll, taxes, and interest of 1.07 M. | |
| IGM Biosciences currently holds about 469.14 M in cash with (192.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| IGM Biosciences has a poor financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Brokerages Set IGM Biosciences, Inc. PT at 16.13 |
- Analyzing IGM Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IGM Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining IGM Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IGM Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of IGM Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IGM Biosciences' stock. These opinions can provide insight into IGM Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.